Vulvar cancer spreads first and most commonly to the inguinal (groin) lymph nodes, which serve as the primary drainage basin for the vulvar region. When the disease travels beyond those nodes, the lungs, liver, and bone are the most frequently affected distant organs, though distant spread remains uncommon compared with local and regional recurrence. The path from a primary vulvar tumor to distant sites follows a fairly predictable sequence, and understanding that sequence matters for both surveillance and treatment decisions.
Groin Lymph Nodes Are the First Stop
The vulva drains lymph fluid primarily into the superficial inguinal nodes in the groin. Because of this anatomy, regional spread to those nodes is the most common form of metastasis in vulvar cancer, particularly in squamous cell carcinoma, which accounts for the vast majority of cases.1PubMed Central. Vulvar carcinoma: dilemma, debates, and decisions Tumors on one side of the vulva tend to drain to the ipsilateral (same-side) groin, but midline tumors or those near the clitoris can drain to both sides, meaning bilateral groin involvement is possible. From the superficial inguinal nodes, disease can progress deeper into pelvic lymph nodes, though pelvic involvement typically signals more advanced staging.
The clinical significance of groin node metastasis is hard to overstate. Lymph node status is the single strongest predictor of survival in vulvar cancer. Patients whose groin nodes are clear after surgical evaluation have substantially better outcomes than those with even one positive node. That reality is why groin node assessment, whether through full inguinofemoral lymphadenectomy or the sentinel lymph node procedure, remains central to the management of this disease.
Where Distant Metastases Show Up
When vulvar cancer does spread beyond the regional lymph nodes, it tends to follow a fairly consistent pattern. A study documenting distant metastatic sites in vulvar cancer found that the lung was the most common destination, followed by the liver, bone, skin, and distant lymph node groups such as axillary, thoracic, or para-aortic nodes.2Gynecologic Oncology. Patterns of distant metastases in vulvar cancer This ranking broadly mirrors what happens in other squamous cell cancers of the lower genital tract, where the lungs tend to be the first organ seeded via the bloodstream.
Bloodborne (hematogenous) spread in vulvar squamous cell carcinoma is rare when the groin nodes are clear. It almost always occurs in the context of advanced disease where nodes are already involved.3PubMed Central. Unusual vulvar cancer recurrence after radical vulvectomy with negative margins: a case report This means that for a patient whose surgical pathology shows no lymph node involvement, the chance of waking up with lung or liver metastases years later is very low, though not zero.
Rare and Unexpected Metastatic Sites
While lungs, liver, and bone account for the typical distant spread, case reports document vulvar cancer reaching places clinicians rarely expect. One widely described case involved a woman whose vulvar squamous cell carcinoma recurred aggressively after more than a year of remission, with metastases to the clavicle, the phalanges (finger bones), and the brain. Her finger began bleeding due to a metastatic lesion that eroded through tissue and bone, requiring amputation. She also developed a pathologic fracture of the clavicle from metastatic disease and needed surgery and radiation for the brain lesions.4Journal of Reproductive Medicine Gynaecology & Obstetrics. Recognizing Rare Metastatic Presentations of Vulvar Cancer to Bone and Brain: A Short Review A detailed report of the same case noted that post-treatment imaging also revealed lung and hip bone metastases, and the finger lesion represented the first documented case of vulvar cancer spreading to the soft tissue of the phalanges and requiring amputation.5Gynecologic Oncology Reports. Rare phalanges soft tissue and bony metastasis in vulvar squamous cell carcinoma: Case report
Bone metastases from vulvar cancer in general are uncommon but recognized. A separate case report described a patient who developed a pathologic fracture of the humerus (upper arm bone) four months after initial treatment. A bone scan revealed additional metastatic lesions in both humeral heads and the distal femur. The authors concluded that bone metastases should be considered when a patient with a history of vulvar cancer develops unexplained bone pain.6PubMed. Bone metastases in vulvar cancer: a rare metastatic pattern These cases are important not because they are common, but because they illustrate that once vulvar cancer becomes widely metastatic, it can show up almost anywhere, and unusual pain or symptoms in a patient with a vulvar cancer history should not be dismissed.
What Increases the Risk of Distant Spread
Not everyone with positive groin nodes goes on to develop distant metastases. The risk climbs sharply with specific pathologic features in the affected nodes. A study examining lymph node characteristics found that among patients who had a combination of extracapsular spread (cancer breaking through the node’s outer capsule), replacement of more than half the node by tumor, and three or more positive nodes, nearly half developed distant metastases.7PubMed. Extracapsular growth of lymph node metastases in squamous cell carcinoma of the vulva. The impact on recurrence and survival That combination essentially signals a tumor that has overwhelmed the regional lymphatic system and gained the ability to seed distant organs.
For patients without nodal involvement, or with only a single microscopically involved node and no extracapsular spread, the risk of distant metastasis is much lower. The practical takeaway is that the surgical pathology report after groin node dissection or sentinel node biopsy carries crucial prognostic information. The number of involved nodes, whether cancer has broken through the node capsule, and the proportion of the node replaced by tumor all factor into predicting whether distant disease is likely to follow.
Recurrence Patterns After Initial Treatment
Understanding where vulvar cancer metastasizes also means understanding when and how it comes back after treatment. A nationwide population-based study found that among patients who experienced recurrence, about 61% had isolated local recurrence at the vulvar site, about 30% had groin recurrence (sometimes combined with local recurrence), and roughly 9% had distant recurrences.8Gynecologic Oncology. Patterns of recurrence and survival in vulvar cancer: A nationwide population-based study Local recurrence at the vulvar site was by far the most common pattern.
The timing of these different recurrence types differs in a clinically important way. Groin and distant recurrences tend to appear early, with median times to recurrence of about 9 months and 6.5 months respectively, while local recurrences take much longer to develop, with a median time of about 26 months.8Gynecologic Oncology. Patterns of recurrence and survival in vulvar cancer: A nationwide population-based study The rate of new groin and distant recurrences was nearly steady between two and five years after treatment, suggesting that if these types of recurrence are going to happen, they usually happen within the first couple of years. Local recurrences, by contrast, kept accumulating steadily out to five years and beyond. A separate single-center study with a ten-year follow-up reported an overall recurrence rate of about 27%, consistent with the broader literature.9PubMed Central. Lymph Node Metastasis and Patterns of Recurrence in Vulvar Carcinoma: 10 Years’ Single Center Experience
Another analysis found a 32% overall recurrence rate, with roughly 20% local, 6% regional, and 6% distant.10PubMed. Predictors and Patterns of Recurrence in Vulvar Cancer The consistent finding across these studies is that distant metastasis as a pattern of recurrence is the least common of the three but carries the worst prognosis. Local recurrences, while more frequent, are often salvageable with further surgery or radiation.
How Metastases Are Found
Detecting whether vulvar cancer has spread beyond the primary site is a challenge because the disease does not always announce itself with obvious symptoms. PET/CT scanning (using a radioactive glucose tracer) has become an increasingly important tool. One study found that PET/CT detected suspicious lymph nodes in about 35% of scans performed and identified distant metastases in 10 cases, outperforming conventional CT alone, which found distant disease in only 5 cases. PET/CT also caught abnormalities that conventional CT missed entirely.11PubMed Central. The impact of FDG-PET/CT in the management of patients with vulvar and vaginal cancer
PET/CT is not perfect for groin node evaluation, however, and the reported accuracy varies quite a bit between studies. One study found relatively modest sensitivity and specificity for detecting groin node metastases (around 50% and 67% respectively on a per-patient basis).12PubMed Central. 18F-FDG PET/CT in preoperative staging of vulvar cancer patients: is it really effective? A larger single-center study found much higher sensitivity at about 91%, with a negative predictive value of nearly 97%, meaning a negative PET/CT scan was very reassuring for ruling out groin metastases.13Journal of Clinical Images and Medical Case Reports. The value of preoperative FDG PET/CT in detecting groin metastases in vulvar cancer patients The discrepancy likely reflects differences in patient populations, tumor sizes, and imaging protocols. In practice, most centers still rely on surgical staging of the groin (sentinel node biopsy or full lymphadenectomy) as the gold standard, with PET/CT playing a complementary role, especially in identifying distant disease or planning treatment for recurrent cancer.
Sentinel Lymph Nodes and Micrometastasis
The sentinel node procedure, which identifies the first node(s) draining the tumor for targeted removal and analysis, has reduced the need for complete groin dissection in many patients. One important refinement involves ultrastaging, where the sentinel node is sliced into multiple thin sections and examined with special staining. In one study, more than a third of patients with metastatic sentinel nodes had micrometastases that were only found through this detailed ultrastaging process and would have been missed on standard pathologic examination. When sentinel nodes were negative, no other nodes contained cancer, giving a 100% negative predictive value.14Gynecologic Oncology. Further Data on the Usefulness of Sentinel Lymph Node Identification and Ultrastaging in Vulvar Squamous Cell Carcinoma Detecting these tiny deposits matters because even micrometastatic disease in a groin node changes staging, prognosis, and treatment decisions.
Does the Type of Vulvar Cancer Matter
Most vulvar cancers are squamous cell carcinomas, and the metastatic patterns described above apply primarily to that histology. Within squamous cell carcinoma, there are two biologically distinct pathways: one driven by human papillomavirus (HPV) infection and one that develops independently of HPV, often in the setting of chronic skin conditions like lichen sclerosus. Despite clear molecular differences between these two subtypes, research has found that HPV status did not significantly affect overall survival or progression-free survival.15PubMed Central. Human Papillomavirus‒Positive and ‒Negative Vulvar Squamous Cell Carcinoma Are Biologically but Not Clinically Distinct In other words, the two subtypes behave differently at the molecular level but do not seem to produce meaningfully different clinical outcomes in terms of spread or survival, at least with current evidence.
Vulvar melanoma, a much rarer form, follows a different and generally more aggressive course. Melanoma has a well-known tendency to metastasize early and unpredictably to a wide range of organs, including the brain, and vulvar melanoma is no exception. Patients with distant metastatic vulvar melanoma have particularly poor outcomes. One analysis found that two-year overall survival with distant metastatic disease was only about 12% for patients not receiving immunotherapy, with a modestly higher rate of roughly 33% for those treated with immunotherapy, though this difference did not reach statistical significance.16PubMed Central. Vulvar melanoma: an analysis of prognostic factors and treatment patterns Vulvar melanoma is staged and treated differently from squamous cell carcinoma, and the metastatic patterns overlap with melanoma at other body sites more than with squamous vulvar cancer.
Treating Metastatic Vulvar Cancer
Once vulvar cancer has spread to distant organs, treatment shifts from curative intent to disease control and palliation. Historically, options for metastatic vulvar squamous cell carcinoma have been limited, with platinum-based chemotherapy and radiation forming the backbone of treatment. One case report described a patient with recurrent metastatic disease who was treated with cisplatin plus cetuximab (an antibody targeting the epidermal growth factor receptor) alongside palliative radiation, achieving a partial response that lasted about five months.17PubMed. Recurrent metastatic vulvar carcinoma treated with cisplatin plus cetuximab Responses like that are often short-lived, which speaks to how difficult metastatic vulvar cancer is to control.
Immunotherapy has opened new avenues, though the results so far have been modest for most patients. A scoping review of targeted therapy and immunotherapy in advanced vulvar squamous cell carcinoma found that the immune checkpoint inhibitor pembrolizumab produced response rates of roughly 6% to 11% across two major trials, with median overall survival ranging from about 4 to 6 months. Nivolumab showed a 20% response rate. Combination strategies performed somewhat better; pembrolizumab with vorinostat yielded a median overall survival of about 17.5 months, while the combination of ipilimumab and nivolumab achieved about 7.6 months. A newer agent, toripalimab, reported a 33% response rate.18PubMed. Efficacy and safety of targeted therapy and immunotherapy in advanced vulvar squamous cell carcinoma: A scoping review These numbers are preliminary and come from relatively small studies, but they represent genuine progress in a disease that had almost no systemic treatment options a decade ago.
Molecular profiling is also starting to influence treatment for individual patients. In one case, a woman with HER2-amplified vulvar adenocarcinoma (a rare non-squamous subtype) who had failed prior therapies achieved a complete and durable response to trastuzumab deruxtecan, an antibody-drug conjugate targeting HER2, and remained disease-free after a year of follow-up.19PubMed Central. Complete and durable response to trastuzumab deruxtecan in HER2-amplified invasive vulvar adenocarcinoma: A case report That is a single case, but it illustrates a broader principle gaining traction across oncology: tumor-agnostic therapies matched to the specific molecular features of a cancer can sometimes produce striking results even in rare tumors where no standard treatment protocol exists.
Why Vulvar Cancer Metastasis Is Understudied
Vulvar cancer accounts for a small fraction of all gynecologic cancers, which means large-scale prospective studies of its metastatic behavior are rare. Much of what clinicians know about distant spread comes from case reports, retrospective chart reviews, and national registry analyses rather than randomized trials. The disease also tends to affect older women, a group historically underrepresented in clinical trials. This combination of low incidence and an older patient population means that evidence for optimal management of metastatic vulvar cancer lags well behind what is available for more common cancers like cervical or ovarian.
The relative scarcity of data also means that clinicians sometimes extrapolate from cervical cancer trials when choosing systemic therapies for advanced vulvar cancer. Both are predominantly squamous cell cancers of the lower genital tract, and both can be driven by HPV. But they are not identical diseases, and treatment responses do not always translate directly from one to the other. As immunotherapy and molecularly targeted treatments become more accessible, the hope is that vulvar cancer will accumulate its own trial-level evidence rather than continuing to borrow from neighboring diagnoses. For patients dealing with metastatic disease right now, the practical advice is to ask about clinical trials, because many of the newer agents showing early promise are still being studied in that setting.